AbbVie (ABBV) has witnessed a mix of advancements and setbacks recently. The stock has exhibited resilience amidst market dips, leading some investors to closely monitor it. The healthcare company had moments of appreciation, but also saw some declines, triggering various trading sentiments. Significant news includes the selling of AbbVie shares at $175, investment in Sionna for a licensing deal concerning cystic fibrosis drugs, and collaboration with Gilgamesh Pharmaceuticals to develop therapies for psychiatric disorders.
The company faced regulatory challenges with FDA rejecting its Duopa successor in Parkinson's twice due to 3rd-party manufacturer issues. However, it managed to secure CHMP nod for lymphoma drug’s expanded usage and FDA's approval for Epkinly's label expansion. In addition, ABBV's acquisition of Landos Biopharma aimed to strengthen its portfolio in the inflammatory and autoimmune diseases segment. AbbVie also filed for Rinvoq in giant cell arteritis in the US and EU.
Anticipated Q2 earnings decline has been a concern, yet, the post Gonzalez era is expected to start positively. Also noteworthy has been AbbVie's new deal enhancing its neuropsychiatric portfolio and furthermore, a price target increase by BMO Capital Markets at 214$.
Abbvie ABBV News Analytics from Mon, 22 Jan 2024 08:00:00 GMT to Sun, 21 Jul 2024 06:33:13 GMT - Rating 4 - Innovation 6 - Information 5 - Rumor -2
